China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max Foundation (Max) to improve access to the Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries. The three-year collaboration aims to enhance access to this critical treatment for CLL, the most common leukemia in adults, which accounts for about one-third of new leukemia cases worldwide and results in around 40,000 deaths annually.
BeiGene’s Commitment to Global Health
BeiGene is committed to donating supplies of Brukinsa and making a grant available through the BeiGene Foundation. This initiative aligns with the company’s mission to improve global health outcomes by providing access to innovative therapies for patients in need.
Max Foundation’s Role in Expanding Access
The Max Foundation will partner with leading physicians in target low- and middle-income countries in the second half of 2023 to establish an access pathway for patients to gain access to Brukinsa. The NGO’s efforts are particularly focused on making treatments available at no cost in countries where patients would otherwise have limited access to adequate care, with a specific emphasis on cancer treatments.
Max Foundation’s Existing Programs
The Max Foundation currently has programs in place for renal cell carcinoma, gastrointestinal stromal tumor, and chronic myeloid leukemia, demonstrating its broad commitment to improving cancer care globally.-Fineline Info & Tech
